Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Summary
The purpose of this phase II study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol is effective in patients with resectable and unresectable pancreatic cancer.
General Information
NCT#: NCT03138720
Study ID: NABPLAGEM-NEO 2017-001
Trial Phase: Phase II
Trial Sponsor: HonorHealth Research Institute
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cisplatin, Paricalcitol